Primary endpoint of 5 phase III randomized trials will be presented during ESMO - Eur. Oncology 2020, including 1st ADC in TNBC and 1st adjuvant trials testing cdk4/6 inh.

Vote Now: I voted in the ASCO election. Join me in casting your vote by December 8. asco.org/election #ivoted via Asco

Sara Tolaney Hassan Shahryar Sheikh, MD FACP OncoAlert Great news! nejm.org/do/10.1056/NEJ…

Pembrolizumab improves OS in triple negative MBC. Terrific news for our patients today #breastcancer merck.com/news/merck-ann…

Inacreditável uma pessoa do nível do senador Fabiano Contarato ter que dedicar um tempo de seu impecável mandato para defender sua família. Já é passada a hora de se ter respeito com as pessoas

The 1st ⁦ESMO - Eur. Oncology⁩ guidelines on metastatic breast cancer have just been published with some important messages about the positioning of tdxd , palb2 mutations, alpelisib , IO and adc in tnbc... under the great leadership of Alessandra Gennari annalsofoncology.org/article/S0923-…

Check out the new guidelines that are going to be published or the St Gallen consensus

🇧🇷✨ Brazilian presentation 🇧🇷✨ Izabela Porto and co-authors: Body weight modification during adjuvant ovarian suppression for premenopausal women with luminal breast cancer in a Cancer Center in Brazil. Happening today at #SABCS24 👀 Marcelle Goldner Cesca Solange Sanches